SCHEMBL3849889

SCHEMBL3849889

CON[C@@H](Cc1c(C)n(Cc2cccc(OC(F)(F)F)c2)c2ccccc12)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.53
PLA2G2A P14555 7/20 0.50
ADAM17 P78536 2/20 0.49
PPARA Q07869 7/20 0.49
CYP2C9 P11712 2/20 0.49
EGFR P00533 1/20 0.49
CHRM4 P08173 1/20 0.49
ADRB1 P08588 1/20 0.49
ADRA2A P08913 1/20 0.49
ALOX5 P09917 1/20 0.49
ADRB3 P13945 1/20 0.49
DRD2 P14416 1/20 0.49
ADRA2B P18089 1/20 0.49
CHRM3 P20309 1/20 0.49
TACR2 P21452 1/20 0.49
DRD1 P21728 1/20 0.49
TBXA2R P21731 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
OPRM1 P35372 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849887 1.00 PPARG (0.53) PPARGPLA2G2AADAM17PPARACYP2C9
SCHEMBL3858100 0.90 ADAM17 (0.56) PPARGPLA2G2AADAM17CYP2C9CYP1A2
SCHEMBL3858097 0.90 ADAM17 (0.56) PPARGPLA2G2AADAM17CYP2C9CYP1A2
SCHEMBL3854171 0.86 PLA2G2A (0.48) PLA2G2AADAM17PLA2G1B
SCHEMBL3854169 0.86 PLA2G2A (0.48) PLA2G2AADAM17PLA2G1B
SCHEMBL2004289 0.83 PLA2G2A (0.59) PPARGPLA2G2APPARACYP2C9EGFR
SCHEMBL3854426 0.83 PLA2G2A (0.49) PPARGPLA2G2AADAM17PLA2G1B
SCHEMBL3854423 0.83 PLA2G2A (0.49) PPARGPLA2G2AADAM17PLA2G1B
SCHEMBL3855493 0.82 ADAM17 (0.54) PPARGPLA2G2AADAM17CYP2C9CYP1A2
SCHEMBL3855489 0.82 ADAM17 (0.54) PPARGPLA2G2AADAM17CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 PPARG 4511/4885PLA2G2A 3197/4885ADAM17 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.